Skip Navigation
United States Flag

An official website of the United States government. Here's how you know >

A New Look for HHS-OIG. Learn More >>

U.S. Flag An official website of the United States government.
Change Font Size

Report (OEI-03-12-00410)

Comparison of Fourth-Quarter 2011 Average Sales Prices and Average Manufacturer Prices: Impact on Medicare Reimbursement for Second Quarter 2012

Complete Report

Download the complete report

Adobe® Acrobat® is required to read PDF files.



This review was conducted in accordance with the statutory mandate for the Office of Inspector General (OIG) to identify Medicare Part B prescription drugs with average sales prices (ASP) that exceed average manufacturer prices (AMP) by at least 5 percent. This review estimated the financial impact of lowering reimbursement amounts for drugs that met the 5-percent threshold to 103 percent of the AMPs, and also examined the potential effect of a July 2012 proposed rule that, among other things, specifies the circumstances under which the Centers for Medicare & Medicaid Services (CMS) will make AMP-based price substitutions.

Office of Inspector General, U.S. Department of Health and Human Services | 330 Independence Avenue, SW, Washington, DC 20201